

4.0.3 DOC Cmte minutes

Parkinson's disease guideline committee meeting

Date: 11/09/2015

Location: Dee, NICE Offices Manchester, Piccadilly Plaza, M1 4BT

Minutes: Draft

Committee members present:	
Paul Cooper (Chair)	Present for all
Graham Lennox (GL)	Present for all
Lynne Osbourne	Present to the end of item 6
Fiona Lindop (FL)	Present for all
Paul Shotbolt (PS)	Present for all
Amanda Wardle (co-opted expert)	Present from the beginning to end of item 2
Clare Johnson (co-opted expert)	Present for all
Julian Evans (co-opted expert)	Present from item 4 to the end
Ivan Benett (IB)	Present for all
Jane Little (JL)	Present for all
Janine Barnes (JB)	Present for all
Matthew Sullivan (MS)	Present for all
Debbie Davies (DD)	Present until the end of item 6
Richard Walker (RW)	Present for all
Robin Fackrell (RF)	Present for all

4.0.3 DOC Cmte minutes

In attendance:		
Laura Downey	Technical Analyst	Present for all
Gabriel Rogers	Technical Adviser – Health Economics	Present for all
Steven Ward	Health Economist	Present for all
Maggie Derry	Project Manager	Present for all
Louise Picton	Technical Adviser – Medicines Prescribing Centre	Present from item 3
Louise Bate	Associate Director – Medicines Prescribing Centre	Present from item 3

Observers:	
Maxim Grunewald	NICE Intern

Committee member apologies:	
Richard Grunewald	Committee member
Alistair Church	Committee member

1. Welcome, introductions, minutes, DoI and matters arising			
<p>The Chair welcomed the Committee members and attendees to the seventh meeting on Parkinson’s disease. The Committee members and attendees introduced themselves.</p> <p>The Chair asked those present to declare any conflicts of interest relevant to the areas being discussed or potential new conflicts. No new conflicts were declared with the following exceptions</p>			
Name	Declaration	Classification	Chairs action
Robin Fackrell (RF)	1. Chairing meeting for UCB in December. No honorarium will be received	Personal non-financial interest	Declare and participate
	2. Speaking engagement at	Personal, non-financial, specific	Declare and

4.0.3 DOC Cmte minutes

	the Parkinson's Disease nurse specialist conference. Non remunerated	interest	participate
Richard Walker (RW)	<ol style="list-style-type: none"> 1. Principal investigator for a drug study with UCB on ritigotine. Fees are used to pay for research nurses for the department. 2. Involved in a study on the drug safinamide, which is not licensed for use in the UK. 3. Speaking engagement at the Parkinson's Disease nurse specialist conference. Non remunerated 	<p>Non personal financial, specific interest</p> <p>Personal, non-financial, non-specific interest</p> <p>Personal non-financial, specific, interest</p>	<p>Declare and participate. It was also suggested that RW step down as the Principal Investigator for the study.</p> <p>Declare and participate</p> <p>Declare and participate</p>
Debbie Davies (DD)	Speaking engagement at the Parkinson's Disease nurse specialist conference. Non remunerated	Personal non-financial, specific, interest	Declare and participate

The committee reviewed the minutes of the previous meeting and agreed they were an accurate record of the discussions.

The Chair noted that there is currently no further update to give on NHS England's decision to commission duodopa. The guideline will continue with the work currently

4.0.3 DOC Cmte minutes

planned and the committee will be informed if there is any change.

2. RQ7 - Effectiveness of occupational therapy on the complications of PD

LD presented the evidence highlighting that 1 paper met the inclusion criteria which was of a high quality. It was noted that the PD rehab study is not as yet published but will be included in the re-runs if it is published in time.

The committee noted that occupational therapists look at a broad range of issues, which is not recognised in the study. It was also considered important to ensure the occupational therapist has specialist knowledge of Parkinson's disease.

SW presented health economic literature. The trial directly measured Quality of Life, which is a rare occurrence.

The Committee debated the quality of the evidence and considered their experiences of the benefits of occupational therapy and disadvantages of making recommendations on this specific aspect of sleep alone. The group went on to make recommendations.

3. RQ22 – Comparative effectiveness of pharmacological interventions to treat RBD

LD presented the evidence for the committee to consider. Evidence was of a low quality.

The Committee discussed their clinical practice and experiences in using pharmacological treatments for RBD and discussed the need for more research in this area. They then went on to make a recommendation and a research recommendation.

4. Health economics modelling update

SW gave an update on data received in response to the call for evidence. He highlighted the data that had been received and noted that no trial data had been received on duration of treatment for duodopa that is greater than 12 weeks.

SW noted that LD and GR had met with the team for the PDSurg trial, which was a very productive meeting. The Committee discussed the value of receiving additional data for a number of different areas and agreed which would be most useful.

The Committee were advised that due to the additional analysis required, not all of which has been received, it won't be possible to complete planned work for the October GDG, this will need to be deferred to later in 2016. The 2 day October meeting will therefore be rearranged to a 1 day meeting. A poll will be circulated to agree which of the existing March and June GDG's will be extended to a 2 day

4.0.3 DOC Cmte minutes

meeting.

An update was also given on the structure and development of the health economic model. SW noted further studies for inclusion, once the data is available. The Committee discussed the proposed structure and addressed the queries raised.

5. Linking evidence to recommendations (LETR) tables

The Committee reviewed the draft summary of their earlier discussions about how the draft recommendations were formulated (LETR tables).

These were agreed as an accurate record. It was confirmed the tables would be written up in full prose and sent out to the committee in the week following the meeting.

6. Review protocol 20 - cognitive enhancement in dementia associated with Parkinson's disease

LP recapped the review protocol and took the committee through some queries around the defined population and studies for exclusion. The group discussed these and reached a consensus opinion.

7. Summary and next steps

The Chair thanked the group for their attendance and contributions.

MD confirmed the dates of the next meeting, advised that the LETR tables and chapters will be circulated for information and confirmed the date and location of the next meeting.

Date of next meeting: 19th October 2015

Location of next meeting: NICE Offices, Manchester